KR920008048A - 광학 활성 티에노트리아졸로디아제핀 화합물 - Google Patents

광학 활성 티에노트리아졸로디아제핀 화합물 Download PDF

Info

Publication number
KR920008048A
KR920008048A KR1019910017987A KR910017987A KR920008048A KR 920008048 A KR920008048 A KR 920008048A KR 1019910017987 A KR1019910017987 A KR 1019910017987A KR 910017987 A KR910017987 A KR 910017987A KR 920008048 A KR920008048 A KR 920008048A
Authority
KR
South Korea
Prior art keywords
carbon atoms
alkyl
optically active
crystal
hydrogen
Prior art date
Application number
KR1019910017987A
Other languages
English (en)
Other versions
KR940006633B1 (ko
Inventor
미노루 모리와끼
슈지 유아사
히로유끼 기따니
미찌오 데라사와
Original Assignee
고야 마사시
요시또미세이야꾸 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 고야 마사시, 요시또미세이야꾸 가부시끼가이샤 filed Critical 고야 마사시
Publication of KR920008048A publication Critical patent/KR920008048A/ko
Application granted granted Critical
Publication of KR940006633B1 publication Critical patent/KR940006633B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

내용 없음.

Description

광학 활성 티에노트리아졸로디아제핀 화합물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. 하기 일반식(I)의 광학 활성 티에노트리아졸로디아제핀 화합물의 산부가염 또는 그의 수화물의 안정한 결정
    (식중, R1은 수소, R2는 탄소수 1∼5개의 알킬로 치환된 2-페닐에틸,2-모르폴리노카르보닐에틸 또는 탄소수 6∼12개의 알킬이거나, R1및 R2는 결합하여 모르폴리노메틸, 모르폴리노카르보닐 및 N,N-디프로필카르바모일로 구성된 군에서 선택되는 하나의 치환기가 있는 포화된 5원환을 형성할 수 있으며, R3는 할로겐, 탄소수 1∼5개의 알킬 또는 탄소수 1∼5개의 알콕시이고, R4는 트리플루오로메틸 또는 탄소수 1∼5개의 알킬이며, R5는 수소 또는 메틸이고, m은 1∼2, n은 0∼2이다.)
  2. 하기 일반식(II)
    (식중, 각각의 기호는 제1항에서 정의한 바와같다.)로 나타나는 광학 활성 티에노트리아졸로디아제핀 화합물을 하기 일반식(III)
    (식중, R5는 제1항에서 정의한 바와같다.)으로 나타나는 산 또는 2수화물과 반응시켜 수득되는 하기 일반식(I)
    (식중, 각각의 기호는 제1항에서 정의한 바와같다.)의 광학 활성 티에노트리아졸로디아제핀 산부가염 또는그 수화물의 안정한 결정.
  3. 제1항에 있어서, R3이 염소, R4가 메틸임을 특징으로 하는 인정한 결정.
  4. 제1항에 있어서, R1이 수소, R2가 2-(4-이소부틸페닐)에틸 또는 2-모르폴리노카르브닐에틸, R3는 염소이며 R4가 메틸임을 특징으로 하는 안정한 결정.
  5. 제 1항에 있어서, 결정이 6S-(-) -4-(2-클로로페닐) -2-(2-(4-이소부틸페닐)에틸) -6,9-디메틸-6H-티에노[3,2-f][1,2,4]트리아졸로[4,3-a][1,4]디아제핀 p-톨루엔 술폰산염임을 특징으로 하는 안정한 결정.
  6. 제1항에 있어서, 결정이 6S-(-)-3-[4-(2-클로로페닐)-6,9-디메틸 -6H-티에노[3,2-f][1,2,4]트리아졸로[4,3-a][1,4]디아제핀-2-일]프로피온산 모르폴리드 3/2 p-톨루엔 술폰산염 3/2 수화물임을 특징으로 하는 안정한 결정.
  7. 제1항에 있어서, 결정이 6S-(-) -3-[4-(2-클로로페닐) -6,9-디메틸-6H-티에노[3,2-f][1,2,4]트리아졸로[4,3-a][1,4]디아제핀-2-일]프로피온산모르폴리드 3/2 벤젠술폰산염 3/2 수화물임을 특징으로 하는 안정한 결정.
    ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.
KR1019910017987A 1990-10-12 1991-10-12 광학 활성 티에노트리아졸로디아제핀 화합물 KR940006633B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP27445190 1990-10-12
JP90-274451 1990-10-12
JP21451291 1991-07-31
JP91-214512 1991-07-31

Publications (2)

Publication Number Publication Date
KR920008048A true KR920008048A (ko) 1992-05-27
KR940006633B1 KR940006633B1 (ko) 1994-07-23

Family

ID=26520357

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910017987A KR940006633B1 (ko) 1990-10-12 1991-10-12 광학 활성 티에노트리아졸로디아제핀 화합물

Country Status (9)

Country Link
US (1) US5286858A (ko)
EP (1) EP0480455B1 (ko)
JP (1) JP2959598B2 (ko)
KR (1) KR940006633B1 (ko)
AT (1) ATE148122T1 (ko)
CA (1) CA2053123A1 (ko)
DE (1) DE69124330T2 (ko)
DK (1) DK0480455T3 (ko)
ES (1) ES2099114T3 (ko)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638560A4 (en) * 1991-10-11 1995-03-29 Yoshitomi Pharmaceutical MEDICINE FOR OSTEOPOROSIS AND DIAZEPINE COMPOUND *.
US7955607B2 (en) * 2004-07-13 2011-06-07 Taiho Pharmaceutical Co., Ltd. Method of evaluating evenness of suplatast tosilate crystal, even crystal, and process for producing the same
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
US9422292B2 (en) 2011-05-04 2016-08-23 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
EP2864336B1 (en) 2012-06-06 2016-11-23 Constellation Pharmaceuticals, Inc. Benzo[b]isoxazoloazepine bromodomain inhibitors and uses thereof
EP3157928B1 (en) 2014-06-20 2019-02-13 Constellation Pharmaceuticals, Inc. Crystalline forms of 2-((4s)-6-(4-chlorophenyl)-1-methyl-4h-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide
US11992494B2 (en) 2021-12-22 2024-05-28 Boehringer Ingelheim International Gmbh Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0268242B1 (en) * 1986-11-17 1992-03-18 Yoshitomi Pharmaceutical Industries, Ltd. Paf-antagonistic thienotriazolodiazepine compounds and pharmaceutical uses thereof
US4960770A (en) * 1987-05-28 1990-10-02 Yoshitomi Pharmaceutical Industries, Ltd. 2-alkyl thieno(triazolo)diazepine compounds and pharmaceutical uses thereof
MC1999A1 (fr) * 1987-12-18 1990-01-26 Hoffmann La Roche Composes tricycliques
CA1324863C (en) * 1988-01-30 1993-11-30 Minoru Moriwaki Thienotriazolodiazepine compounds and pharmaceutical uses thereof
DE4010528A1 (de) * 1990-04-02 1991-10-17 Boehringer Ingelheim Kg Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine

Also Published As

Publication number Publication date
DE69124330T2 (de) 1997-07-03
EP0480455A1 (en) 1992-04-15
US5286858A (en) 1994-02-15
DK0480455T3 (da) 1997-02-10
ATE148122T1 (de) 1997-02-15
DE69124330D1 (de) 1997-03-06
KR940006633B1 (ko) 1994-07-23
ES2099114T3 (es) 1997-05-16
JPH0586067A (ja) 1993-04-06
JP2959598B2 (ja) 1999-10-06
CA2053123A1 (en) 1992-04-13
EP0480455B1 (en) 1997-01-22

Similar Documents

Publication Publication Date Title
DE50100893D1 (de) Verfahren zur Herstellung von 3,4-Alkylendioxythiophen-2,5-dicarbonsäurederivaten
ES2059069T3 (es) Nuevos derivados de 1-alcoxi-(2-acilamino-etil)-naftalenos y su procedimiento de preparacion.
IE801070L (en) Phenylsulphonamides
KR920008048A (ko) 광학 활성 티에노트리아졸로디아제핀 화합물
AT384424B (de) Verfahren zur herstellung von neuen 3-hydroxy-2-oxo-pyrrolidinderivaten und ihren salzen
KR890017244A (ko) 6-페닐-3-(피페라지닐알킬)-2,4-(1h,3h)-피리미딘디온 유도체, 그의 제법 및 치료에의 이용
KR850008488A (ko) 디히드로이미다조 [1,2-a] 피리미딘 유도체류의 제조방법
ES478871A1 (es) Un procedimiento de preparacion de 2,6-dialcoxibenzamidas.
NO924634L (no) Nye oksazolderivater, deres fremstilling samt preparater inneholdende forbindelsene
SE7709158L (sv) Nya substituerade 2-fenylaminoimidazolin-(2)-er, syraadditionssalter derav, lekemedel som innehaller dessa och forfarande for framstellning derav
KR850000455A (ko) 세팔로스포린 에스테르 유도체의 제조방법
JPS5589282A (en) Ergolene derivative*its manufacture and medical composition containing it and having antihypertensive and antiprolactin activity
KR920005986A (ko) 혈소판 응집 억제용 약제학적 조성물
ATE9333T1 (de) Substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben.
ATE22081T1 (de) Substituierte thienobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
KR840006810A (ko) 세팔로스포린 에스테르의 제조방법
ATE7913T1 (de) Substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben.
KR850004758A (ko) 피라졸로 피리딘 유도체의 제법
NO874211D0 (no) Fremgangsmaate til fremstilling av aralkyl-4h-1,2,4-triazolderivater.
ES8607944A1 (es) Procedimiento para la preparacion de nuevos derivados de 1- fenilimidazolidin-2-ona
TH15829A (th) อนุพันธ์คาร์โบสไทริล
TH14567A (ko)
TH35859A (th) อนุพันธ์พิร์โรโลพิร์โรโลน
TH2417A (th) อนุพันธุ์ไดไฮโดรเบนโซไพแรน
TH13562A (th) สารประกอบทางเภสัช

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20010608

Year of fee payment: 8

LAPS Lapse due to unpaid annual fee